Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma
| Autor: | Christina Stilling, Frede Donskov, Hans Henrik Torp Madsen, Patricia Switten Nielsen, Kennet Thorup, Finn Rasmussen, Aska Drljevic-Nielsen, Jill Rachel Mains |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Necrosis Angiogenesis Biopsy CD34 Urology R895-920 Contrast Media Blood volume Carcinoma (renal cell) Tomography (x-ray computed) 030218 nuclear medicine & medical imaging Metastasis 03 medical and health sciences Medical physics. Medical radiology. Nuclear medicine 0302 clinical medicine Renal cell carcinoma medicine Humans Radiology Nuclear Medicine and imaging Carcinoma Renal Cell Neuroradiology business.industry Microvascular density Blood flow medicine.disease Prognosis Kidney Neoplasms 030220 oncology & carcinogenesis Original Article medicine.symptom business Tomography X-Ray Computed |
| Zdroj: | European Radiology Experimental, Vol 5, Iss 1, Pp 1-12 (2021) European Radiology Experimental Drljevic-Nielsen, A, Rasmussen, F, Nielsen, P S, Stilling, C, Thorup, K, Mains, J R, Madsen, H H T & Donskov, F 2021, ' Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma ', European Radiology Experimental, vol. 5, no. 1, 32 . https://doi.org/10.1186/s41747-021-00232-2 |
| ISSN: | 2509-9280 |
| DOI: | 10.1186/s41747-021-00232-2 |
| Popis: | Background Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results At baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration NCT01274273 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink